SCHEMBL10126036

SCHEMBL10126036

Cc1ccc2nc(-c3ccc(-c4ccc(-c5nc6ccccc6nc5-c5ccc(-c6ccc(-c7nc8ccc(C)cc8o7)cc6)cc5)cc4)cc3)oc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.65
RAB9A P51151 12/20 0.65
MMP2 P08253 1/20 0.58
MMP9 P14780 1/20 0.58
MMP8 P22894 1/20 0.58
MMP13 P45452 1/20 0.58
HSD17B10 Q99714 5/20 0.57
KDM4E B2RXH2 10/20 0.57
ALDH1A1 P00352 10/20 0.57
HPGD P15428 9/20 0.57
SMN1; SMN2 Q16637 9/20 0.57
MAPT P10636 5/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
TDP1 Q9NUW8 2/20 0.57
TP53 P04637 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125852 0.97 NPC1 (0.62) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL10315409 0.89 NPC1 (0.55) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL10126033 0.89 KDM4E (0.73) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL10125924 0.88 TDP1 (0.60) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL19601392 0.88 NPC1 (0.72) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL10315173 0.88 NPC1 (0.54) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL12408905 0.86 NPC1 (0.84) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL10125853 0.86 KDM4E (0.78) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL436386 0.85 NPC1 (0.76) NPC1RAB9AMMP2MMP9MMP8
SCHEMBL11551873 0.85 NPC1 (0.81) NPC1RAB9AMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885MMP2 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.